Atlas Trials

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

Clinical trial NCT02300558 · TERMINATED

Trial details

NCT number
NCT02300558
Sponsor
Gilead Sciences
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Long QT Syndrome Type 3
Start date
2014-12-17
Primary completion
2016-12-12
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.